Paper Details

  1. Home
  2. Paper Details

Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: Results from ASTRAL-1 placebo-controlled trial.

Author: AgarwalKosh, FeldJordan, HenryLinda, HezodeChristophe, HuntSharon, JacobsonIra, NaderFatema, StepanovaMaria, YounossiZobair M, ZeuzemStefan

Controlled Clinical TrialA clinical trial that evaluates the effectiveness of a treatment by comparing a group that receives the intervention with a group that receives a placebo or standard treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Treatment with sofosbuvir and velpatasvir for hepatitis C virus infection significantly improves patient-reported outcomes, such as general health, emotional well-being, and quality of life. These improvements are seen during treatment and after achieving sustained virologic response.
Paper Details　
Original Abstract of the Article :
BACKGROUND & AIMS: The new pan-genotypic regimen [sofosbuvir (SOF) and velpatasvir (VEL)] for hepatitis C virus (HCV) has been associated with high efficacy. The aim of this study was to assess patient-reported outcomes (PROs) of this regimen. METHODS: The PRO data (CLDQ-HCV, SF-36, FACIT-F, WPAI) ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.jhep.2016.02.042

データ提供：米国国立医学図書館（NLM）

Sofosbuvir/velpatasvir: A Game Changer for Hepatitis C Patients

Hepatitis C is a serious liver infection that can lead to long-term health complications. The development of new treatment regimens has revolutionized the management of this disease, and this study examines the impact of a combination therapy, sofosbuvir/velpatasvir, on patient-reported outcomes. The researchers used data from the ASTRAL-1 trial, a multicenter study that compared the new regimen to placebo in patients with different genotypes of hepatitis C.

The results revealed that sofosbuvir/velpatasvir significantly improved patient-reported outcomes, including general health, emotional well-being, and quality of life, compared to placebo. This suggests that the new regimen not only effectively treats the infection but also improves the overall well-being of patients.

Sofosbuvir/velpatasvir: A Hope for Hepatitis C Patients

These findings are highly encouraging for hepatitis C patients. The study demonstrates the potential of sofosbuvir/velpatasvir to not only eradicate the virus but also enhance the quality of life for patients. The significant improvements in patient-reported outcomes highlight the importance of considering the overall well-being of patients, not just the clinical markers of disease.

Sofosbuvir/velpatasvir: A New Era of Treatment for Hepatitis C

The development of effective and well-tolerated treatment regimens has significantly changed the landscape of hepatitis C management. This study highlights the potential of sofosbuvir/velpatasvir to improve the lives of patients not only by treating the infection but also by enhancing their overall well-being. It’s a positive step forward in the fight against this debilitating disease.

Dr.Camel's Conclusion

Imagine a camel traversing a harsh desert, carrying a heavy burden. Now picture a refreshing oasis offering respite and nourishment. That’s what sofosbuvir/velpatasvir represents for hepatitis C patients. This groundbreaking therapy not only clears the virus but also brings a newfound sense of well-being and hope to those affected by this challenging disease.

Date :
  1. Date Completed 2018-04-23
  2. Date Revised 2022-03-31
Further Info :

Pubmed ID

26956698

DOI: Digital Object Identifier

10.1016/j.jhep.2016.02.042

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.